person · Reporting owner

NEA 14 GP, LTD

Disclosed activity across 14 companies

Tapewire entity: 23292
SEC CIK: 0001551532

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Adaptimmune Therapeutics PLCADAP · Entity 9824	10% owner	September 07, 2018	September 10, 2018
CHAMPIONS ONCOLOGY, INC.CSBR · Entity 7013	10% owner	March 06, 2020	March 10, 2020
Galera Therapeutics, Inc.GRTX · Entity 15899	10% owner	November 12, 2019	November 12, 2019
SYNLOGIC, INC.SYBX · Entity 7801	Director · 10% owner	July 27, 2026	August 14, 2026
Strongbridge Biopharma plcSBBP · Entity 131608	10% owner	January 01, 2018	January 09, 2018
Tracon Pharmaceuticals, Inc.TCON · Entity 91134	10% owner	March 27, 2018	March 27, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Adaptimmune Therapeutics PLC

Report date September 07, 2018 · Filed September 10, 2018

Jointly reported with New Enterprise Associates 14, L.P., NEA Partners 14, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares with a nominal value of 0.001 GBP per shareSEC Table I · non-derivative	Direct	82,978,668	Reported balance After 2018-09-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-09-07 · Purchase · Acquired 3,000,000 · Balance 82,978,668 F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs. F2: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six. F3: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.

F2: The price reported in Column 4 of $1.6667 per ordinary share is a price derived from the price of $10.00 per ADS, divided by six.

F3: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

CHAMPIONS ONCOLOGY, INC.

Report date March 06, 2020 · Filed March 10, 2020

Jointly reported with New Enterprise Associates 14, L.P., Sonsini Peter W., Florence Anthony A. Jr., BASKETT FOREST, KERINS PATRICK J, NEA Partners 14, L.P., SANDELL SCOTT D

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,713,720	Last balance in matching sequence After 2020-03-06 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-03-06 · Other · Acquired 859,375 · Balance 2,421,875 F1: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Row 2 · 2020-03-06 · Sale · Disposed 708,155 · Balance 1,713,720 F2: On March 6, 2020, NEA 14 exercised a warrant to purchase a total of 859,375 shares of Issuer's common stock for $5.76 a share. NEA 14 paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 708,155 of the warrant shares to pay the exercise price and issuing 151,220 shares to NEA 14. F1: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
Warrant to Purchase Common Stock (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2020-03-13	Direct	0	Reported balance After 2020-03-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-03-06 · Other · Disposed 859,375 · Balance 0 F1: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

F2: On March 6, 2020, NEA 14 exercised a warrant to purchase a total of 859,375 shares of Issuer's common stock for $5.76 a share. NEA 14 paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 708,155 of the warrant shares to pay the exercise price and issuing 151,220 shares to NEA 14.

Galera Therapeutics, Inc.

Report date November 12, 2019 · Filed November 12, 2019

Jointly reported with New Enterprise Associates 14, L.P., Sonsini Peter W., KERINS PATRICK J, NEA Partners 14, L.P., BARRIS PETER J, BASKETT FOREST, Florence Anthony A. Jr., MOTT DAVID M, SANDELL SCOTT D

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,358,047	Last balance in matching sequence After 2019-11-12 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 4 source rows Row 1 · 2019-11-12 · Conversion · Acquired 1,774,922 · Balance 1,774,922 F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Row 2 · 2019-11-12 · Conversion · Acquired 1,898,524 · Balance 3,673,446 F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Row 3 · 2019-11-12 · Conversion · Acquired 267,935 · Balance 3,941,381 F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Row 4 · 2019-11-12 · Purchase · Acquired 416,666 · Balance 4,358,047 F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
Series A Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-11-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-12 · Conversion · Disposed 8,975,000 · Balance 0 F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-11-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-11-12 · Conversion · Disposed 9,600,000 · Balance 0 F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2019-11-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-11-12 · Conversion · Disposed 1,354,829 · Balance 0 F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis, upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

SYNLOGIC, INC.

Report date July 27, 2026 · Filed August 14, 2026

Jointly reported with New Enterprise Associates 14, L.P., NEA Partners 14, L.P., Florence Anthony A. Jr., SANDELL SCOTT D, Makhzoumi Mohamad

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2028-10-03	Direct	0	Reported balance After 2026-07-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-27 · Other · Disposed 2,640,845 · Balance 0 F2: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $3.408 a share to $0.70 a share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. F1: The warrants were immediately exercisable; provided, however, that the warrants carry a limitation on exercise preventing exercise if such exercise results in New Enterprise Associates 14, L.P. ("NEA 14") beneficially owning in excess of 4.99% (or, at the election of NEA 14, 9.99%) of the number of shares of the Issuer's Common Stock, which percentage can be increased or decreased at the option of NEA 14 upon 61 days' prior notice. F3: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and the members of the Executive Committee (the "Executive Committee") of NEA Management Company, LLC (NEA Partners 14, NEA 14 LTD and the members of the Executive Committee together, the "Indirect Reporting Persons"). The members of the Executive Committee are Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Indirect Reporting Persons have no pecuniary interest.
Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2028-10-03	Direct	2,640,845	Reported balance After 2026-07-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-27 · Purchase · Acquired 2,640,845 · Balance 2,640,845 F2: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $3.408 a share to $0.70 a share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. F1: The warrants were immediately exercisable; provided, however, that the warrants carry a limitation on exercise preventing exercise if such exercise results in New Enterprise Associates 14, L.P. ("NEA 14") beneficially owning in excess of 4.99% (or, at the election of NEA 14, 9.99%) of the number of shares of the Issuer's Common Stock, which percentage can be increased or decreased at the option of NEA 14 upon 61 days' prior notice. F3: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and the members of the Executive Committee (the "Executive Committee") of NEA Management Company, LLC (NEA Partners 14, NEA 14 LTD and the members of the Executive Committee together, the "Indirect Reporting Persons"). The members of the Executive Committee are Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The warrants were immediately exercisable; provided, however, that the warrants carry a limitation on exercise preventing exercise if such exercise results in New Enterprise Associates 14, L.P. ("NEA 14") beneficially owning in excess of 4.99% (or, at the election of NEA 14, 9.99%) of the number of shares of the Issuer's Common Stock, which percentage can be increased or decreased at the option of NEA 14 upon 61 days' prior notice.

F2: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $3.408 a share to $0.70 a share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one.

F3: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and the members of the Executive Committee (the "Executive Committee") of NEA Management Company, LLC (NEA Partners 14, NEA 14 LTD and the members of the Executive Committee together, the "Indirect Reporting Persons"). The members of the Executive Committee are Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Indirect Reporting Persons have no pecuniary interest.

Strongbridge Biopharma plc

Report date January 01, 2018 · Filed January 09, 2018

Jointly reported with Growth Equity Opportunities Fund III, LLC, New Enterprise Associates 14, L.P., NEA Partners 14, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, $0.01 par valueSEC Table I · non-derivative	Direct	4,141,308	Reported balance Holding disclosure · report date 2018-01-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,141,308 F1: The securities are directly held by Growth Equity Opportunities Fund III, LLC ("GEO") and are indirectly held by New Enterprise Associates 14, L.P. ("NEA 14"), which is the sole member of GEO; NEA Partners 14, L.P. ("NEA Partners 14"), which is the sole general partner of NEA 14; NEA 14 GP, LTD ("NEA 14 GP"), which is the sole general partner of NEA Partners 14; and the individual directors of NEA 14 GP (NEA 14, NEA Partners 14, NEA 14 GP and the individual directors of NEA 14 GP (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 GP are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. F2: The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the GEO shares in which the Indirect Reporting Persons have no pecuniary interest.
Ordinary Shares Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2022-06-28	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: The securities are directly held by Growth Equity Opportunities Fund III, LLC ("GEO") and are indirectly held by New Enterprise Associates 14, L.P. ("NEA 14"), which is the sole member of GEO; NEA Partners 14, L.P. ("NEA Partners 14"), which is the sole general partner of NEA 14; NEA 14 GP, LTD ("NEA 14 GP"), which is the sole general partner of NEA Partners 14; and the individual directors of NEA 14 GP (NEA 14, NEA Partners 14, NEA 14 GP and the individual directors of NEA 14 GP (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 GP are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. F2: The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the GEO shares in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by Growth Equity Opportunities Fund III, LLC ("GEO") and are indirectly held by New Enterprise Associates 14, L.P. ("NEA 14"), which is the sole member of GEO; NEA Partners 14, L.P. ("NEA Partners 14"), which is the sole general partner of NEA 14; NEA 14 GP, LTD ("NEA 14 GP"), which is the sole general partner of NEA Partners 14; and the individual directors of NEA 14 GP (NEA 14, NEA Partners 14, NEA 14 GP and the individual directors of NEA 14 GP (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 GP are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan.

F2: The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the GEO shares in which the Indirect Reporting Persons have no pecuniary interest.

Tracon Pharmaceuticals, Inc.

Report date March 27, 2018 · Filed March 27, 2018

Jointly reported with SANDELL SCOTT D, NEA Partners 14, L.P.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Note 2	3,466,003	Reported balance After 2018-03-27 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-03-27 · Purchase · Acquired 707,964 · Balance 3,466,003 F1: Acquired from the issuer pursuant to a Securities Purchase Agreement dated March 22, 2018, with a closing date of March 27, 2018. F2: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2024-03-27	IndirectSee Note 2	707,964	Reported balance After 2018-03-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-27 · Purchase · Acquired 707,964 · Balance 707,964 F1: Acquired from the issuer pursuant to a Securities Purchase Agreement dated March 22, 2018, with a closing date of March 27, 2018. F2: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Acquired from the issuer pursuant to a Securities Purchase Agreement dated March 22, 2018, with a closing date of March 27, 2018.

F2: The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of New Enterprise Associates 14, L.P. ("NEA 14"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.

Past disclosures · reporting ended (8)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

APPIAN CORP

Report date February 13, 2018 · Filed February 15, 2018

Jointly reported with NEA Partners 14, L.P.

Section 16 reporting ended · disclosed 2018-02-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee Note 4	Last balance in matching sequence After 2018-02-13 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-02-13 · Conversion · Acquired 2,724,202 · Balance 2,724,202 F1: Pursuant to the terms of the Class B Common Stock, New Enterprise Associates 14, L.P. ("NEA 14") converted shares of Class B Common Stock into shares of Class A Common Stock. F2: Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of Class A Common Stock and has no expiration date. In addition, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon (1) any transfer, whether or not for value and whether voluntary or involuntary or by operation of law, except for certain transfers described in the Issuer's certificate of incorporation, including, without limitation, certain transfers for tax and estate planning purposes or (continued to Footnote (3)) F3: (continued from Footnote (2)) (2) the death or disability, as defined in the Issuer's certificate of incorporation, of the applicable Class B common stockholder (or nine months after the date of death or disability if the stockholder is one of the Issuer's founders). In addition, on the first trading day following the date on which the outstanding shares of Class B Common Stock represent less than 10% of the aggregate voting power of the Issuer's then outstanding capital stock, all outstanding shares of Class B Common Stock shall convert automatically into Class A Common Stock, and no additional shares of Class B Common Stock will be issued. F4: The shares are directly held by NEA 14 and are indirectly held by the Reporting Person, the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of the Reporting Person and each of the individual directors of NEA 14 LTD (the Reporting Person, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest. Row 2 · 2018-02-13 · Other · Disposed 2,724,202 · Balance 0 F5: NEA 14 made a pro rata distribution for no consideration of an aggregate of 2,724,202 shares of Class A Common Stock of the Issuer to its general partner and its limited partners on February 13, 2018. F4: The shares are directly held by NEA 14 and are indirectly held by the Reporting Person, the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of the Reporting Person and each of the individual directors of NEA 14 LTD (the Reporting Person, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest.
Class A Common StockSEC Table I · non-derivative	Direct	Last balance in matching sequence After 2018-02-13 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 3 · 2018-02-13 · Other · Acquired 27,242 · Balance 27,242 F6: The Reporting Person received 27,242 shares of Class A Common Stock of the Issuer in the distribution by NEA 14 on February 13, 2018. F7: The shares are directly held by the Reporting Person and indirectly held by NEA 14 LTD, the sole general partner of the Reporting Person, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest. Row 4 · 2018-02-13 · Other · Disposed 27,242 · Balance 0 F8: The Reporting Person made a pro rata distribution for no consideration of an aggregate of 27,242 shares of Class A Common Stock of the Issuer to its limited partners on February 13, 2018. F7: The shares are directly held by the Reporting Person and indirectly held by NEA 14 LTD, the sole general partner of the Reporting Person, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest.
Class B Common StockSEC Table II · derivative / convertible security	IndirectSee Note 4	Reported balance After 2018-02-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-02-13 · Conversion · Disposed 2,724,202 · Balance 0 F2: Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of Class A Common Stock and has no expiration date. In addition, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon (1) any transfer, whether or not for value and whether voluntary or involuntary or by operation of law, except for certain transfers described in the Issuer's certificate of incorporation, including, without limitation, certain transfers for tax and estate planning purposes or (continued to Footnote (3)) F3: (continued from Footnote (2)) (2) the death or disability, as defined in the Issuer's certificate of incorporation, of the applicable Class B common stockholder (or nine months after the date of death or disability if the stockholder is one of the Issuer's founders). In addition, on the first trading day following the date on which the outstanding shares of Class B Common Stock represent less than 10% of the aggregate voting power of the Issuer's then outstanding capital stock, all outstanding shares of Class B Common Stock shall convert automatically into Class A Common Stock, and no additional shares of Class B Common Stock will be issued. F1: Pursuant to the terms of the Class B Common Stock, New Enterprise Associates 14, L.P. ("NEA 14") converted shares of Class B Common Stock into shares of Class A Common Stock. F4: The shares are directly held by NEA 14 and are indirectly held by the Reporting Person, the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of the Reporting Person and each of the individual directors of NEA 14 LTD (the Reporting Person, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Class B Common Stock, New Enterprise Associates 14, L.P. ("NEA 14") converted shares of Class B Common Stock into shares of Class A Common Stock.

F2: Each share of Class B Common Stock is convertible at any time at the option of the holder into one share of Class A Common Stock and has no expiration date. In addition, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon (1) any transfer, whether or not for value and whether voluntary or involuntary or by operation of law, except for certain transfers described in the Issuer's certificate of incorporation, including, without limitation, certain transfers for tax and estate planning purposes or (continued to Footnote (3))

F3: (continued from Footnote (2)) (2) the death or disability, as defined in the Issuer's certificate of incorporation, of the applicable Class B common stockholder (or nine months after the date of death or disability if the stockholder is one of the Issuer's founders). In addition, on the first trading day following the date on which the outstanding shares of Class B Common Stock represent less than 10% of the aggregate voting power of the Issuer's then outstanding capital stock, all outstanding shares of Class B Common Stock shall convert automatically into Class A Common Stock, and no additional shares of Class B Common Stock will be issued.

F4: The shares are directly held by NEA 14 and are indirectly held by the Reporting Person, the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of the Reporting Person and each of the individual directors of NEA 14 LTD (the Reporting Person, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest.

F5: NEA 14 made a pro rata distribution for no consideration of an aggregate of 2,724,202 shares of Class A Common Stock of the Issuer to its general partner and its limited partners on February 13, 2018.

F6: The Reporting Person received 27,242 shares of Class A Common Stock of the Issuer in the distribution by NEA 14 on February 13, 2018.

F7: The shares are directly held by the Reporting Person and indirectly held by NEA 14 LTD, the sole general partner of the Reporting Person, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest.

F8: The Reporting Person made a pro rata distribution for no consideration of an aggregate of 27,242 shares of Class A Common Stock of the Issuer to its limited partners on February 13, 2018.

Casper Sleep Inc.

Report date January 25, 2022 · Filed January 26, 2022

Jointly reported with New Enterprise Associates 14, L.P., NEA Partners 14, L.P., BASKETT FOREST, KERINS PATRICK J, SANDELL SCOTT D, Sonsini Peter W.

Section 16 reporting ended · disclosed 2022-01-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-01-25 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-01-25 · Other · Disposed 6,222,502 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2021 (the "Merger Agreement"), by and among Casper Sleep Inc. (the "Issuer"), Marlin Parent, Inc. ("Parent") and Marlin Merger Sub, Inc. ("Merger Sub"). On January 25, 2022, upon the closing of the merger of Merger Sub with and into the Issuer contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.000001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $6.90 (the "Merger Consideration"), without interest, subject to applicable withholding taxes. Includes 90 additional shares received upon conversion of shares of preferred stock in connection with the Issuer's initial public offering and not previously reported. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2021 (the "Merger Agreement"), by and among Casper Sleep Inc. (the "Issuer"), Marlin Parent, Inc. ("Parent") and Marlin Merger Sub, Inc. ("Merger Sub"). On January 25, 2022, upon the closing of the merger of Merger Sub with and into the Issuer contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.000001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $6.90 (the "Merger Consideration"), without interest, subject to applicable withholding taxes. Includes 90 additional shares received upon conversion of shares of preferred stock in connection with the Issuer's initial public offering and not previously reported.

F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Enliven Therapeutics, Inc.

Report date April 05, 2022 · Filed April 07, 2022

Jointly reported with New Enterprise Associates 14, L.P., BASKETT FOREST, Florence Anthony A. Jr., KERINS PATRICK J, SANDELL SCOTT D, Sonsini Peter W., NEA Partners 14, L.P.

Section 16 reporting ended · disclosed 2022-04-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,611,050	Last balance in matching sequence After 2022-04-06 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2022-04-05 · Sale · Disposed 439,088 · Balance 2,866,513 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Row 2 · 2022-04-06 · Sale · Disposed 255,463 · Balance 2,611,050 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

MULESOFT, INC

Report date May 01, 2018 · Filed May 09, 2018

Jointly reported with New Enterprise Associates 14, L.P., NEA Partners 14, L.P.

Section 16 reporting ended · disclosed 2018-05-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2018-05-01 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2018-05-01 · Conversion · Acquired 12,679,970 · Balance 12,679,970 F1: Upon consummation of the tender offer (as described below), each share of tendered Class B common stock converted on a one-to-one basis into Class A common stock. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Row 2 · 2018-05-01 · Other · Disposed 12,679,970 · Balance 0 F3: Pursuant to the Agreement and Plan of Merger, dated as of March 20, 2018 (the "Merger Agreement"), by and among salesforce.com, inc. ("Salesforce"), Malbec Acquisition Corp. and the Issuer, each share of Class A common stock was tendered in exchange for (i) $36.00 in cash and (ii) 0.0711 of a share of Salesforce common stock, together with cash in lieu of any fractional shares of Salesforce common stock. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2018-05-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-05-01 · Conversion · Disposed 12,679,970 · Balance 0 F1: Upon consummation of the tender offer (as described below), each share of tendered Class B common stock converted on a one-to-one basis into Class A common stock. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Upon consummation of the tender offer (as described below), each share of tendered Class B common stock converted on a one-to-one basis into Class A common stock.

F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, David M. Mott, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

F3: Pursuant to the Agreement and Plan of Merger, dated as of March 20, 2018 (the "Merger Agreement"), by and among salesforce.com, inc. ("Salesforce"), Malbec Acquisition Corp. and the Issuer, each share of Class A common stock was tendered in exchange for (i) $36.00 in cash and (ii) 0.0711 of a share of Salesforce common stock, together with cash in lieu of any fractional shares of Salesforce common stock.

Mersana Therapeutics, Inc.

Report date September 14, 2020 · Filed September 16, 2020

Jointly reported with NEA Partners 14, L.P.

Section 16 reporting ended · disclosed 2020-09-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Note 2	5,959,520	Reported balance After 2020-09-14 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-09-14 · Other · Disposed 2,000,000 · Balance 5,959,520 F1: New Enterprise Associates 14, L.P. ("NEA 14") made a pro rata distribution for no consideration of an aggregate of 2,000,000 shares of Common Stock of the Issuer to its general partner and its limited partners on September 14, 2020. F2: The shares are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest.
Common StockSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2020-09-14 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2020-09-14 · Other · Acquired 20,000 · Balance 20,000 F3: NEA Partners 14 received 20,000 shares of Common Stock of the Issuer in the distribution by NEA 14 on September 14, 2020. F4: The shares are directly held by NEA Partners 14 and indirectly held by NEA 14 LTD, the sole general partner of NEA Partners 14, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest. Row 3 · 2020-09-14 · Other · Disposed 20,000 · Balance 0 F5: NEA Partners 14 made a pro rata distribution for no consideration of an aggregate of 20,000 shares of Common Stock of the Issuer to its limited partners on September 14, 2020. F4: The shares are directly held by NEA Partners 14 and indirectly held by NEA 14 LTD, the sole general partner of NEA Partners 14, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: New Enterprise Associates 14, L.P. ("NEA 14") made a pro rata distribution for no consideration of an aggregate of 2,000,000 shares of Common Stock of the Issuer to its general partner and its limited partners on September 14, 2020.

F2: The shares are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest.

F3: NEA Partners 14 received 20,000 shares of Common Stock of the Issuer in the distribution by NEA 14 on September 14, 2020.

F4: The shares are directly held by NEA Partners 14 and indirectly held by NEA 14 LTD, the sole general partner of NEA Partners 14, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest.

F5: NEA Partners 14 made a pro rata distribution for no consideration of an aggregate of 20,000 shares of Common Stock of the Issuer to its limited partners on September 14, 2020.

Oyster Point Pharma, Inc.

Report date January 03, 2023 · Filed January 04, 2023

Jointly reported with New Enterprise Associates 14, L.P., BASKETT FOREST, KERINS PATRICK J, NEA Partners 14, L.P., SANDELL SCOTT D, Sonsini Peter W.

Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2023-01-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-01-03 · Other · Disposed 5,925,287 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F3: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)

F2: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.

F3: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Surface Oncology, Inc.

Report date May 20, 2020 · Filed May 22, 2020

Jointly reported with New Enterprise Associates 14, L.P., NEA Partners 14, L.P., BASKETT FOREST, Florence Anthony A. Jr., KERINS PATRICK J, SANDELL SCOTT D, Sonsini Peter W.

Section 16 reporting ended · disclosed 2020-05-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,892,877	Reported balance After 2020-05-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-05-20 · Sale · Disposed 420,000 · Balance 2,892,877 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $3.91, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $3.91, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F2: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

ZeroFox Holdings, Inc.

Report date May 13, 2024 · Filed May 15, 2024

Jointly reported with New Enterprise Associates 14, L.P., NEA Partners 14, L.P., BASKETT FOREST, Florence Anthony A. Jr., KERINS PATRICK J, SANDELL SCOTT D

Section 16 reporting ended · disclosed 2024-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-05-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-05-13 · Other · Disposed 18,068,513 · Balance 0 F1: Securities are disposed of pursuant to the Agreement and Plan of Merger, dated as of February 6, 2024, by and among the Issuer, ZI Intermediate II, Inc. ("Parent"), and HI Optimus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"). On May 13, 2024, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, each then outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive an amount in cash equal to $1.14 per share without interest thereon and subject to any applicable withholding taxes. F3: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD, and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Filing footnotes · ownership attribution and instrument terms

F1: Securities are disposed of pursuant to the Agreement and Plan of Merger, dated as of February 6, 2024, by and among the Issuer, ZI Intermediate II, Inc. ("Parent"), and HI Optimus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"). On May 13, 2024, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly-owned subsidiary of Parent (the "Merger").

F2: At the effective time of the Merger, each then outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive an amount in cash equal to $1.14 per share without interest thereon and subject to any applicable withholding taxes.

F3: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD, and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 27, 2026 Filed Aug 14, 2026 20:09 UTC	SYNLOGIC, INC. SYBX · Entity 7801	PurchaseWarrants (Right to Buy) · Derivative	2,640,845	Not disclosed Strike: $0.70	Not disclosed	Disclosure SEC source: 0001193125-26-352228 · ownership.xml · derivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · Director · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · Director · 10% owner NEA 14 GP, LTD · CIK 0001551532 · Director · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · Director · 10% owner SANDELL SCOTT D · CIK 0001237289 · Director · 10% owner Makhzoumi Mohamad · CIK 0001630226 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,640,845 Underlying: Common Stock · 2,640,845 shares Expires 2028-10-03 F2 · price: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $3.408 a share to $0.70 a share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. F1 · derivative.exercise_date: The warrants were immediately exercisable; provided, however, that the warrants carry a limitation on exercise preventing exercise if such exercise results in New Enterprise Associates 14, L.P. ("NEA 14") beneficially owning in excess of 4.99% (or, at the election of NEA 14, 9.99%) of the number of shares of the Issuer's Common Stock, which percentage can be increased or decreased at the option of NEA 14 upon 61 days' prior notice. F3 · ownership.direct: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and the members of the Executive Committee (the "Executive Committee") of NEA Management Company, LLC (NEA Partners 14, NEA 14 LTD and the members of the Executive Committee together, the "Indirect Reporting Persons"). The members of the Executive Committee are Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
July 27, 2026 Filed Aug 14, 2026 20:09 UTC	SYNLOGIC, INC. SYBX · Entity 7801	OtherWarrants (Right to Buy) · Derivative	2,640,845	Not disclosed Strike: $3.41	Not disclosed	Disclosure SEC source: 0001193125-26-352228 · ownership.xml · derivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · Director · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · Director · 10% owner NEA 14 GP, LTD · CIK 0001551532 · Director · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · Director · 10% owner SANDELL SCOTT D · CIK 0001237289 · Director · 10% owner Makhzoumi Mohamad · CIK 0001630226 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,640,845 shares Expires 2028-10-03 F2 · price: The two transactions reported in Table II above involved the amendment of an outstanding warrant to reduce the exercise price from $3.408 a share to $0.70 a share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. F1 · derivative.exercise_date: The warrants were immediately exercisable; provided, however, that the warrants carry a limitation on exercise preventing exercise if such exercise results in New Enterprise Associates 14, L.P. ("NEA 14") beneficially owning in excess of 4.99% (or, at the election of NEA 14, 9.99%) of the number of shares of the Issuer's Common Stock, which percentage can be increased or decreased at the option of NEA 14 upon 61 days' prior notice. F3 · ownership.direct: The securities are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and the members of the Executive Committee (the "Executive Committee") of NEA Management Company, LLC (NEA Partners 14, NEA 14 LTD and the members of the Executive Committee together, the "Indirect Reporting Persons"). The members of the Executive Committee are Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 14 in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
May 13, 2024 Filed May 15, 2024 19:30 UTC	ZeroFox Holdings, Inc. ZFOX · Entity 91031	OtherCommon Stock	18,068,513	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-060355 · ownership.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Securities are disposed of pursuant to the Agreement and Plan of Merger, dated as of February 6, 2024, by and among the Issuer, ZI Intermediate II, Inc. ("Parent"), and HI Optimus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"). On May 13, 2024, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: At the effective time of the Merger, each then outstanding share of the Issuer's common stock was canceled and converted automatically into the right to receive an amount in cash equal to $1.14 per share without interest thereon and subject to any applicable withholding taxes. F3 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD, and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins and Scott D. Sandell. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 03, 2023 Filed Jan 4, 2023 22:14 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	OtherCommon Stock	5,925,287	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-001125 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2) F2 · price: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F3 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P., ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
April 06, 2022 Filed Apr 7, 2022 20:54 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	255,463	$1.10	$281,826.78	Disclosure SEC source: 0001209191-22-023686 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,611,050 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.07 to $1.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. F2 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
April 05, 2022 Filed Apr 7, 2022 20:54 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	439,088	$1.07	$469,428.98	Disclosure SEC source: 0001209191-22-023686 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,866,513 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 25, 2022 Filed Jan 26, 2022 01:41 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	102,952	$1.47	$151,802.72	Disclosure SEC source: 0001209191-22-004877 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,305,601 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 25, 2022 Filed Jan 26, 2022 23:02 UTC	Casper Sleep Inc. CSPR · Entity 131068	OtherCommon Stock	6,222,502	$6.90	$42,935,263.80	Disclosure SEC source: 0001209191-22-005111 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2021 (the "Merger Agreement"), by and among Casper Sleep Inc. (the "Issuer"), Marlin Parent, Inc. ("Parent") and Marlin Merger Sub, Inc. ("Merger Sub"). On January 25, 2022, upon the closing of the merger of Merger Sub with and into the Issuer contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.000001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $6.90 (the "Merger Consideration"), without interest, subject to applicable withholding taxes. Includes 90 additional shares received upon conversion of shares of preferred stock in connection with the Issuer's initial public offering and not previously reported. F2 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 24, 2022 Filed Jan 26, 2022 01:41 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	19,984	$1.55	$31,017.17	Disclosure SEC source: 0001209191-22-004877 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,408,553 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 21, 2022 Filed Jan 26, 2022 01:41 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	11,622	$1.67	$19,388.98	Disclosure SEC source: 0001209191-22-004877 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,428,537 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 20, 2022 Filed Jan 20, 2022 22:20 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	6,295	$1.81	$11,385.14	Disclosure SEC source: 0001209191-22-004110 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,440,159 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 19, 2022 Filed Jan 20, 2022 22:20 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	13,412	$1.82	$24,413.86	Disclosure SEC source: 0001209191-22-004110 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,446,454 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 18, 2022 Filed Jan 20, 2022 22:20 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	6,848	$1.89	$12,926.97	Disclosure SEC source: 0001209191-22-004110 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,459,866 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 14, 2022 Filed Jan 14, 2022 22:04 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	9,707	$1.91	$18,583.08	Disclosure SEC source: 0001209191-22-003357 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466,714 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 13, 2022 Filed Jan 14, 2022 22:04 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	7,209	$1.93	$13,885.98	Disclosure SEC source: 0001209191-22-003357 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,476,421 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 12, 2022 Filed Jan 14, 2022 22:04 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	4,634	$2.02	$9,357.44	Disclosure SEC source: 0001209191-22-003357 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,483,630 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 11, 2022 Filed Jan 11, 2022 22:54 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	2,409	$2.04	$4,919.42	Disclosure SEC source: 0001209191-22-002930 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,488,264 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 10, 2022 Filed Jan 11, 2022 22:54 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	1,751	$2.00	$3,502.00	Disclosure SEC source: 0001209191-22-002930 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,490,673 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 07, 2022 Filed Jan 11, 2022 22:54 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	14,600	$2.08	$30,318.36	Disclosure SEC source: 0001209191-22-002930 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,492,424 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 06, 2022 Filed Jan 6, 2022 22:35 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	10,257	$2.16	$22,205.38	Disclosure SEC source: 0001209191-22-002224 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,507,024 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 05, 2022 Filed Jan 6, 2022 22:35 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	8,200	$2.25	$18,439.34	Disclosure SEC source: 0001209191-22-002224 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,517,281 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 04, 2022 Filed Jan 6, 2022 22:35 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	13,459	$2.34	$31,543.86	Disclosure SEC source: 0001209191-22-002224 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,525,481 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
January 03, 2022 Filed Jan 4, 2022 01:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	44,665	$2.34	$104,395.50	Disclosure SEC source: 0001209191-22-000354 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,538,940 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 31, 2021 Filed Jan 4, 2022 01:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	49,953	$2.25	$112,409.24	Disclosure SEC source: 0001209191-22-000354 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,583,605 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 30, 2021 Filed Jan 4, 2022 01:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	21,858	$2.29	$50,065.75	Disclosure SEC source: 0001209191-22-000354 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,633,558 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 29, 2021 Filed Dec 29, 2021 23:35 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	15,196	$2.30	$34,953.84	Disclosure SEC source: 0001209191-21-071531 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · Director · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,655,416 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 28, 2021 Filed Dec 29, 2021 23:35 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	24,580	$2.34	$57,539.32	Disclosure SEC source: 0001209191-21-071531 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · Director · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,670,612 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 27, 2021 Filed Dec 29, 2021 23:35 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	27,651	$2.42	$67,006.67	Disclosure SEC source: 0001209191-21-071531 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · Director · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,695,192 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 23, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	23,961	$2.41	$57,746.01	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 11 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,722,843 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 22, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	20,109	$2.32	$46,679.02	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 10 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,746,804 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 21, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	41,222	$2.32	$95,804.05	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 9 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,766,913 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 20, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	38,123	$2.33	$88,719.85	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 8 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,808,135 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 20, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	47,000	$2.21	$103,884.10	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 7 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,846,258 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 16, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	44,993	$2.23	$100,545.86	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 6 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,893,258 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 15, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	28,817	$2.28	$65,685.47	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 5 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,938,251 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 14, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	15,093	$2.56	$38,642.61	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 4 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,967,068 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 13, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	17,501	$2.83	$49,557.58	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,982,161 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 10, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	8,667	$2.83	$24,541.48	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,999,662 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
December 09, 2021 Filed Dec 27, 2021 21:34 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	SaleCommon Stock	5,666	$2.95	$16,693.17	Disclosure SEC source: 0001209191-21-071262 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,008,329 F1 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:43 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	OtherCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050711 · doc4.xml · nonDerivative · entry 3 NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: NEA Partners 14 made a pro rata distribution for no consideration of an aggregate of 20,000 shares of Common Stock of the Issuer to its limited partners on September 14, 2020. F4 · ownership.direct: The shares are directly held by NEA Partners 14 and indirectly held by NEA 14 LTD, the sole general partner of NEA Partners 14, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:43 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	OtherCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050711 · doc4.xml · nonDerivative · entry 2 NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F3 · kind: NEA Partners 14 received 20,000 shares of Common Stock of the Issuer in the distribution by NEA 14 on September 14, 2020. F4 · ownership.direct: The shares are directly held by NEA Partners 14 and indirectly held by NEA 14 LTD, the sole general partner of NEA Partners 14, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest. Read SEC document
September 14, 2020 Filed Sep 16, 2020 20:43 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	OtherCommon Stock	2,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-050711 · doc4.xml · nonDerivative · entry 1 NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 2 Disclosed balance after: 5,959,520 F1 · kind: New Enterprise Associates 14, L.P. ("NEA 14") made a pro rata distribution for no consideration of an aggregate of 2,000,000 shares of Common Stock of the Issuer to its general partner and its limited partners on September 14, 2020. F2 · ownership.nature: The shares are directly held by NEA 14 and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14, and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest. Read SEC document
May 20, 2020 Filed May 22, 2020 16:56 UTC	Surface Oncology, Inc. SURF · Entity 109857	SaleCommon Stock	420,000	$3.66	$1,535,562.00	Disclosure SEC source: 0001209191-20-031786 · doc4.xml · nonDerivative · entry 1 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,892,877 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $3.91, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
April 09, 2020 Filed Apr 14, 2020 01:09 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	OtherCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024296 · doc4.xml · nonDerivative · entry 3 NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: The Reporting Person made a pro rata distribution for no consideration of an aggregate of 40,000 shares of Common Stock of the Issuer to its limited partners on April 9, 2020. F4 · ownership.direct: The shares are directly held by the Reporting Person and indirectly held by NEA 14 LTD, the sole general partner of the Reporting Person, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest. Read SEC document
April 09, 2020 Filed Apr 14, 2020 01:09 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	OtherCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024296 · doc4.xml · nonDerivative · entry 2 NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F3 · kind: The Reporting Person received 40,000 shares of Common Stock of the Issuer in the distribution by NEA 14 on April 9, 2020. F4 · ownership.direct: The shares are directly held by the Reporting Person and indirectly held by NEA 14 LTD, the sole general partner of the Reporting Person, and the Directors of NEA 14 LTD (NEA 14 LTD and the Directors of NEA 14 LTD together, the "NEA Partners 14 Indirect Reporting Persons"). The NEA Partners 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA Partners 14 shares in which the NEA Partners 14 Indirect Reporting Persons have no pecuniary interest. Read SEC document
April 09, 2020 Filed Apr 14, 2020 01:09 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	OtherCommon Stock	4,000,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-024296 · doc4.xml · nonDerivative · entry 1 NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 2 Disclosed balance after: 7,959,520 F1 · kind: New Enterprise Associates 14, L.P. ("NEA 14") made a pro rata distribution for no consideration of an aggregate of 4,000,000 shares of Common Stock of the Issuer to its general partner and its limited partners on April 9, 2020. F2 · ownership.nature: The shares are directly held by NEA 14 and are indirectly held by the Reporting Person, the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of the Reporting Person and each of the individual directors of NEA 14 LTD (the Reporting Person, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, "Directors") together, the "NEA 14 Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Patrick J. Kerins, Scott D. Sandell and Peter W. Sonsini. The NEA 14 Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the NEA 14 Indirect Reporting Persons have no pecuniary interest. Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	ConversionSeries B Preferred Stock · Derivative	5,625,926	$0.00	$0.00	Disclosure SEC source: 0001209191-20-019337 · doc4.xml · derivative · entry 5 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 893,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.exercise_date: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · derivative.expiration_date: On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	ConversionSeries A Preferred Stock · Derivative	15,323,454	$0.00	$0.00	Disclosure SEC source: 0001209191-20-019337 · doc4.xml · derivative · entry 4 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,432,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	ConversionSeries Seed Preferred Stock · Derivative	1,342,780	$0.00	$0.00	Disclosure SEC source: 0001209191-20-019337 · doc4.xml · derivative · entry 3 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 213,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of further consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F4 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document
March 16, 2020 Filed Mar 16, 2020 21:15 UTC	Enliven Therapeutics, Inc. IMRA · Entity 4024	PurchaseCommon Stock	475,000	$16.00	$7,600,000.00	Disclosure SEC source: 0001209191-20-019337 · doc4.xml · nonDerivative · entry 2 New Enterprise Associates 14, L.P. · CIK 0001544328 · 10% owner Sonsini Peter W. · CIK 0001559807 · 10% owner NEA Partners 14, L.P. · CIK 0001551531 · 10% owner NEA 14 GP, LTD · CIK 0001551532 · 10% owner BASKETT FOREST · CIK 0001277631 · 10% owner Florence Anthony A. Jr. · CIK 0001559827 · 10% owner KERINS PATRICK J · CIK 0001235112 · 10% owner SANDELL SCOTT D · CIK 0001237289 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,013,995 F4 · ownership.direct: The securities are directly held by New Enterprise Associates 14, L.P. ("NEA 14") and are indirectly held by NEA Partners 14, L.P. ("NEA Partners 14"), the sole general partner of NEA 14, NEA 14 GP, LTD ("NEA 14 LTD"), the sole general partner of NEA Partners 14 and each of the individual directors of NEA 14 LTD (NEA Partners 14, NEA 14 LTD and the individual directors of NEA 14 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 14 LTD are Forest Baskett, Anthony A. Florence, Jr., Patrick J. Kerins, Scott D. Sandell and Peter Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 securities in which the Indirect Reporting Persons have no pecuniary interest. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.